Product Description
a five Ðamino-acid peptide derived from the synergy region of fibronectin. ATN-161 is a noncompetitive inhibitor of the fibronectin PHSRN sequence, in which a cysteine residue has been substituted for arginine along with peptide acetylation and amidation in order to yield a product with acceptable pharmaceutical properties (Ac-PHSCN-NH2). Unlike other integrin antagonists ATN-161 does not block integrin-dependent adhesion, but may inhibit integrin-dependent signalling as part of its mechanism of action (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361324/)
Mechanisms of Action: SOD Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Attenuon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Brain Stem Cancer|Glioma|Renal Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
06-C-0170 | P2 |
Completed |
Brain Stem Cancer|Glioma |
2007-01-01 |
|
ATN-161-005 | P2 |
Terminated |
Renal Cell Carcinoma |
None |